A retrospective, quantitative assessment of disease burden in patients with leptomeningeal metastases from non-small-cell lung cancer.
Kathryn S Nevel, Natalie DiStefano, Xuling Lin...
https://pubmed.ncbi.nlm.nih.gov/32352148/Actively Recruiting
Led by British Columbia Cancer Agency · Updated on 2026-10-19
10
Participants Needed
1
Research Sites
N/A
Total Duration
Leptomeningeal disease is a serious condition where cancer cells spread to the membranes surrounding the brain and spinal cord, often causing symptoms that affect quality of life. This trial focuses on patients with EGFR mutant non-small cell lung cancer NSCLC who develop leptomeningeal disease while being treated with various generations of tyrosine kinase inhibitors. The study aims to understand molecular differences between cancer DNA found in the cerebrospinal fluid CSF and blood plasma to better characterize the disease in the central nervous system. Participants will undergo diagnostic testing involving lumbar puncture to collect cerebrospinal fluid and blood draws to obtain circulating tumor DNA ctDNA. Molecular profiling will be done using ddPCR and the BC Cancer Next Generation Sequencing panel on both CSF and plasma samples. Baseline brain and spine MRI scans will be completed before enrollment to ensure safety of lumbar puncture. No treatment is given as part of the study, but clinical information and treatments received after enrollment will be recorded. During the study, participants will complete quality of life questionnaires every 12 weeks and survival will be tracked through medical records. The volume of leptomeningeal disease will be measured by counting gadolinium-enhancing sites on MRI at predefined locations. Researchers will assess the agreement between molecular profiles from CSF and plasma over a 36-month period, along with correlations between MRI results, treatment recommendations, and overall survival.
CONDITIONS
CSF Analysis in EGFR Mutant Non-Small Cell Lung Cancer With Leptomeningeal Disease
C
Cheryl Ho, MD
B
Barbara Melosky, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
British Columbia Cancer Agency
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 baseline MRI brain and spine scan
Duration - Up to 36 months
Participants undergo lumbar puncture and blood draws to collect samples for molecular testing. Quality of life questionnaires are completed every 12 weeks, and survival is tracked through medical records. MRI scans are used to assess leptomeningeal disease volume.
Quality of life questionnaires every 12 weeks; periodic MRI scans
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Kathryn S Nevel, Natalie DiStefano, Xuling Lin...
https://pubmed.ncbi.nlm.nih.gov/32352148/Michael D White, Robert H Klein, Brian Shaw...
https://pubmed.ncbi.nlm.nih.gov/34369989/British Columbia Cancer Agency
Lead Sponsor